Compare Motorola Solutions Inc (MSI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Tango Therapeutics Inc. — how do they compare? Motorola Solutions Inc trades at $455.13 (market cap $74.76B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Motorola Solutions Inc is far larger — about 20× Tango Therapeutics Inc.'s market cap, and Motorola Solutions Inc pays a 1.07% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 101 Days and Tango Therapeutics Inc. for 0 Days on average.
| MSI | TNGX | |
|---|---|---|
Market Cap | $74.76B | $3.74B |
Volume | 541,174 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $491.24 | $32.90 |
52-Week Low | $363.83 | $7.50 |
Typical Hold Time | 101 Days | 0 Days |
Enterprise Value | $83.67B | $2.76B |
Dividend Yield | 1.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $449.01, up 0.64% today, with a neutral technical signal. The company shows strong fundamentals: revenue grew to $11.68B in 2025, net income margin is 17.44%, and it has beaten EPS estimates for three consecutive quarters. Recent news includes a $1.5B acquisition of D-Fend Solutions and a $139M public safety contract in Louisiana, highlighting growth in defense and security segments. Cash flow from operations is robust at $2.84B, though net cash flow was negative due to significant investing activities.
Outlook is positive given analyst consensus of a $525.86 price target and 70.59% buy ratings, supported by record backlog and strategic acquisitions. Risks include high valuation multiples (P/E 35.38) and increased debt levels, with net cash flow turning negative in 2025-2026. The stock offers growth potential in mission-critical solutions but faces execution risks from integration of recent buys and competitive pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
